Chemo-immunotherapy before chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer that has spread to nearby lymph nodes but not to distant organs (except the lymph node above the collarbone is allowed).
- You have not had any prior chemotherapy, radiation, immunotherapy, or other cancer treatments.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, kidney function, and liver function are within acceptable ranges.
- You can provide a tissue sample from your tumor (either fresh or stored within the last 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests an immunotherapy drug (adebrelimab) combined with chemotherapy before standard chemoradiation for people with locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.